Reviewed August 2026 by the Corydalis Labs Technical Team. How we research and review.
The honest framing first
13-OH is a synergist. At the inclusion rates that make commercial sense — 25 to 40 milligrams per serving — it does relatively little on its own and a great deal alongside other actives. We lead with that because your own evaluation will tell you the same thing within an afternoon, and a supplier who oversold it would simply be wasting your sample.
We also want to be clear about evidence. The published literature on the parent alkaloid, tetrahydropalmatine, is considerably more developed than the literature on the 13-OH derivative. Much of what is known about how 13-OH behaves in a finished product is formulator and customer observation, not controlled study. Where that is the case, we say so in the sentence rather than dressing it up.
What it contributes to a blend
Across the brands we supply, three observations come back consistently when 13-OH is added to a mitragynine-forward product:
Reduced sensory harshness
The most common complaint about mitragynine-forward formats is how they sit with the user physically. Blends including 13-OH are reported as noticeably smoother in this respect. This is the single most cited reason brands adopt it, and it is the one that shows up fastest in a bench comparison against an existing product.
A fuller overall character
Products read as rounder and more complete rather than one-dimensional. This is subjective language because the observation is subjective — it comes from panels and customer feedback, not instrumentation.
A lower mitragynine requirement
Because 13-OH contributes to the finished profile, formulators find they can reach their target with less mitragynine per serving. This is the effect we consider most important: it shortens the ingredient statement, lightens the total alkaloid load, and makes a product easier to stand behind. The MIT + 13 page covers how brands actually implement it.
Mechanism — what is and is not established
The parent alkaloid THP is described in the literature as interacting principally with dopaminergic signalling rather than opioid receptors. That is the clearest pharmacological distinction between corydalis alkaloids and the kratom alkaloids, which are discussed in terms of opioid receptor activity.
Hydroxylation of an alkaloid commonly changes absorption, persistence, and target engagement, which is consistent with what formulators observe — more contribution per milligram from the derivative than from the parent. But we are not going to assert a specific receptor-level mechanism for 13-OH that the published record does not support. If that is the level of detail your programme needs, the correct answer is your own pharmacology work, not our marketing copy.
What we will not tell you
We do not make claims that any product diagnoses, treats, cures, or prevents any disease, and we do not describe 13-OH in terms of intoxication or as a substitute for anything controlled. Those claims are both unlawful in consumer marketing and corrosive to the category. Our compliant marketing guide explains where the lines sit.
On its own
Standalone use requires substantially more material — generally above 100 milligrams — and even then it performs better paired with caffeine or another botanical stimulant than alone. Brands building kratom-free stimulant products use it this way successfully. Brands hoping it will carry a product by itself at 30 milligrams will be disappointed, and we would rather they heard that from us. Dosing guidance in detail.
How to evaluate it properly
The only assessment that will convince you is your own. What works:
- Bench it against your current product, not against nothing. The differences show up in comparison and are easy to miss in isolation.
- Hold everything else constant. Same format, same flavour system, same mitragynine level in the control. Change one variable.
- Try the reduced-MIT version too. Run a third sample with 13-OH added and mitragynine reduced. That is where the commercial case usually becomes obvious.
- Use a panel, not one person. Sensory observations are noisy at n=1.
Our sample kit is built for exactly this: 10 grams of material for $400, with finished tablet and shot samples so you can assess the compound and the delivery format together.
Common questions
We are not able to answer that in consumer terms, and we would be wary of any supplier who did. What we can tell you is what formulators report in finished blends: reduced sensory harshness, a fuller overall character, and the ability to hit a target profile at a lower mitragynine inclusion. Your own panel evaluation is the meaningful test.
The comparison does not really work — they are unrelated compounds doing different things in a formulation, not two grades of the same thing. 13-OH is a synergist that improves a blend; it is not a like-for-like substitute that reproduces another compound’s profile. The comparison page explains why.
Duration in a finished product depends on the whole formula, the format, and the other actives present — a liquid shot and a pressed tablet do not behave identically even with the same inclusion. We do not publish a duration figure for the isolated compound because it would mislead more than it informed.
We are not in a position to make safety determinations about any compound, and we would not present an opinion as fact. What we can say is that the corydalis alkaloids are discussed in the literature in terms of dopaminergic rather than opioid activity, and that 13-OH is not a kratom alkaloid. Anyone formulating a consumable product should conduct their own safety assessment. Our safety page covers what formulators should consider.
Standard drug-screening panels test for specific substances and their metabolites. 13-OH is not a target on standard panels, but we cannot speak to any particular test, laboratory, or protocol, and we would not want a customer relying on us for that. Direct specific questions to the testing provider.